BCVA indicates best-corrected visual acuity; CMT, central macular thickness; TMV, total macular volume. Mixed-design ANOVA with one within-subject factor (time: 5 levels) and one between-subject factor (group: 2 levels). The main effect of time on BCVA (F(2.032, 52.827) = 8.999, = 0.0004, partial eta2 = 0.257), CMT (F(2.973, 77.295) = 9.419, , partial eta2 = 0.266), and TMV (F(2.345, 60.957) = 11.420, , partial eta2 = 0.305) was statistically significant. The main effect of time-group interaction and the group was not statistically significant (all values >0.05, Table 5). A post hoc pairwise comparison showed a significant improvement in BCVA values from baseline to the 18th and 24th months of treatment ( and , respectively). There was a significant reduction in CMT values from baseline to the 12th, 18th, and 24th months of treatment (, , and , respectively). The reduction in TMV values was significant from baseline to the 6th, 12th, 18th, and 24th months of treatment (, , , and , respectively). All other pairwise comparisons for BCVA, CMT, and TMV values were not statistically significant.